Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Return on Equity (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Return on Equity for 9 consecutive years, with 0.12% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity fell 151.0% to 0.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.12%, a 151.0% decrease, with the full-year FY2025 number at 0.64%, down 110.0% from a year prior.
  • Return on Equity was 0.12% for Q4 2025 at Akebia Therapeutics, up from 0.45% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 8.45% in Q1 2023 to a low of 14.3% in Q4 2022.
  • A 5-year average of 0.69% and a median of 0.28% in 2025 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: plummeted -1161bps in 2022, then skyrocketed 1579bps in 2023.
  • Akebia Therapeutics' Return on Equity stood at 2.69% in 2021, then crashed by -431bps to 14.3% in 2022, then surged by 110bps to 1.48% in 2023, then fell by -6bps to 1.39% in 2024, then tumbled by -108bps to 0.12% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Return on Equity are 0.12% (Q4 2025), 0.45% (Q3 2025), and 1.36% (Q2 2025).